Assumptions of Expected Benefits in Randomized Phase III Trials Evaluating Systemic Treatments for Cancer
نویسندگان
چکیده
منابع مشابه
Assumptions of expected benefits in randomized phase III trials evaluating systemic treatments for cancer.
BACKGROUND In designing phase III randomized clinical trials (RCTs), the expected magnitude of the benefit of the experimental therapy (δ) determines the number of patients required and the number of person-years of follow-up. We conducted a systematic review to evaluate how reliably δ approximates the observed benefit (B) in RCTs that evaluated cancer treatment. METHODS RCTs evaluating syste...
متن کاملAbsolute benefits of medical therapies in phase III clinical trials for breast and colorectal cancer.
BACKGROUND Phase III randomized clinical trials (RCTs) have become larger and are powered to detect small absolute benefits. Temporal changes in absolute benefits of experimental medical therapies reported in RCTs are unknown. METHODS We identified all RCTs with sample size > or =200 evaluating experimental medical therapies for breast and colorectal cancer published from 1975 to 2007. We ass...
متن کاملHospice benefits and phase I cancer trials.
Medicare denies hospice coverage to patients with terminal illnesses who enroll as participants in phase I studies, which assess the toxicity and dosing of potential treatments for incurable diseases. Federal regulations require patients to forgo curative therapies, and they interpret phase I agents as treatment for the terminal condition for which hospice care was elected. Thus, by enrolling a...
متن کاملBreast cancer follow-up strategies in randomized phase III adjuvant clinical trials: a systematic review
UNLABELLED The effectiveness of different breast cancer follow-up procedures to decrease breast cancer mortality are still an object of debate, even if intensive follow-up by imaging modalities is not recommended by international guidelines since 1997. We conducted a systematic review of surveillance procedures utilized, in the last ten years, in phase III randomized trials (RCTs) of adjuvant t...
متن کاملNew treatments compared to established treatments in randomized trials.
BACKGROUND The proportion of proposed new treatments that are 'successful' is of ethical, scientific, and public importance. We investigated how often new, experimental treatments evaluated in randomized controlled trials (RCTs) are superior to established treatments. OBJECTIVES Our main question was: "On average how often are new treatments more effective, equally effective or less effective...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: JNCI Journal of the National Cancer Institute
سال: 2012
ISSN: 0027-8874,1460-2105
DOI: 10.1093/jnci/djs141